David Foulad

1.3k total citations
17 papers, 1.0k citations indexed

About

David Foulad is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, David Foulad has authored 17 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Immunology. Recurrent topics in David Foulad's work include Immunotherapy and Immune Responses (6 papers), Virus-based gene therapy research (5 papers) and CAR-T cell therapy research (5 papers). David Foulad is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), Virus-based gene therapy research (5 papers) and CAR-T cell therapy research (5 papers). David Foulad collaborates with scholars based in United States, France and Netherlands. David Foulad's co-authors include Michael Cerniglia, Begonya Comin-Anduix, Amanda Lassen, Mohammad Atefi, Deborah J. Wong, Thomas G. Graeber, Antoni Ribas, Earl Avramis, Lídia Robert and Bjoern Titz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Clinical Cancer Research.

In The Last Decade

David Foulad

17 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Foulad United States	13	481	414	371	213	113	17	1.0k
Johannes L. Zakrzewski United States	16	296 0.6×	357 0.9×	540 1.5×	110 0.5×	83 0.7×	42	1.1k
Francis Mussai United Kingdom	18	510 1.1×	438 1.1×	591 1.6×	128 0.6×	56 0.5×	40	1.4k
Francesca Pantaleoni Italy	19	425 0.9×	794 1.9×	603 1.6×	141 0.7×	81 0.7×	29	1.3k
Ryosuke Uchibori Japan	17	288 0.6×	452 1.1×	120 0.3×	291 1.4×	232 2.1×	27	915
Fotis Asimakopoulos United States	20	557 1.2×	538 1.3×	333 0.9×	54 0.3×	105 0.9×	40	1.3k
Erika Zonari Italy	9	534 1.1×	886 2.1×	700 1.9×	145 0.7×	106 0.9×	14	1.5k
Unja Martin United States	5	216 0.4×	416 1.0×	573 1.5×	148 0.7×	123 1.1×	7	1.3k
Tad Kornaga United States	8	250 0.5×	400 1.0×	359 1.0×	127 0.6×	50 0.4×	12	870
Cédric Dos Santos United States	16	571 1.2×	762 1.8×	396 1.1×	147 0.7×	169 1.5×	36	1.5k

Countries citing papers authored by David Foulad

Since Specialization

Citations

This map shows the geographic impact of David Foulad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Foulad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Foulad more than expected).

Fields of papers citing papers by David Foulad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Foulad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Foulad. The network helps show where David Foulad may publish in the future.

Co-authorship network of co-authors of David Foulad

This figure shows the co-authorship network connecting the top 25 collaborators of David Foulad. A scholar is included among the top collaborators of David Foulad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Foulad. David Foulad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Zhou, Qi, et al.. (2023). Modulating Temporospatial Phosphate Equilibrium by Nanoparticulate Mineralized Collagen Materials Induces Osteogenesis via PiT‐1 and PiT‐2. Advanced Healthcare Materials. 12(17). e2202750–e2202750. 8 indexed citations

Ren, Xiaoyan, Qi Zhou, David Foulad, et al.. (2019). Osteoprotegerin reduces osteoclast resorption activity without affecting osteogenesis on nanoparticulate mineralized collagen scaffolds. Science Advances. 5(6). eaaw4991–eaaw4991. 50 indexed citations

Foulad, David, et al.. (2019). Assessing patient satisfaction among ABHRS surgeons: Opportunities to improve. Journal of Cosmetic Dermatology. 19(2). 462–465. 1 indexed citations

Ren, Xiaoyan, Qi Zhou, David Foulad, et al.. (2019). Nanoparticulate mineralized collagen glycosaminoglycan materials directly and indirectly inhibit osteoclastogenesis and osteoclast activation. Journal of Tissue Engineering and Regenerative Medicine. 13(5). 823–834. 25 indexed citations

Atefi, Mohammad, Bjoern Titz, Earl Avramis, et al.. (2015). Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Molecular Cancer. 14(1). 27–27. 51 indexed citations

Shweikeh, Faris, David Foulad, Miriam Nuño, Doniel Drazin, & Matthew A. Adamo. (2015). Differences in surgical outcomes for patients with craniosynostosis in the US: impact of socioeconomic variables and race. Journal of Neurosurgery Pediatrics. 17(1). 27–33. 63 indexed citations

Atefi, Mohammad, Earl Avramis, Amanda Lassen, et al.. (2014). Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. Clinical Cancer Research. 20(13). 3446–3457. 285 indexed citations

Wong, Deborah J., Lídia Robert, Mohammad Atefi, et al.. (2014). Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Molecular Cancer. 13(1). 194–194. 85 indexed citations

Candolfi, Marianela, Gwendalyn D. King, Kader Yagiz, et al.. (2012). Plasmacytoid Dendritic Cells in the Tumor Microenvironment: Immune Targets for Glioma Therapeutics. Neoplasia. 14(8). 757–IN26. 38 indexed citations

10.

Candolfi, Marianela, Kurt M. Kroeger, Weidong Xiong, et al.. (2011). Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation. Anti-Cancer Agents in Medicinal Chemistry. 11(8). 729–738. 12 indexed citations

11.

Castro, María G., Marianela Candolfi, Kurt M. Kroeger, et al.. (2011). Gene Therapy and Targeted Toxins for Glioma. Current Gene Therapy. 11(3). 155–180. 62 indexed citations

12.

Candolfi, Marianela, James F. Curtin, Kader Yagiz, et al.. (2011). B Cells Are Critical to T-cell—Mediated Antitumor Immunity Induced by a Combined Immune-Stimulatory/Conditionally Cytotoxic Therapy for Glioblastoma. Neoplasia. 13(10). 947–IN23. 86 indexed citations

13.

Candolfi, Marianela, James F. Curtin, Kader Yagiz, et al.. (2010). Abstract 1909: B cells present tumor antigen and mediate anti-tumor immunity induced by a combined immune-stimulatory/conditional cytotoxic therapy for glioblastoma. Cancer Research. 70(8_Supplement). 1909–1909. 1 indexed citations

14.

Muhammad, A.K.M. Ghulam, Mariana Puntel, Marianela Candolfi, et al.. (2010). Study of the Efficacy, Biodistribution, and Safety Profile of Therapeutic Gutless Adenovirus Vectors as a Prelude to a Phase I Clinical Trial for Glioblastoma. Clinical Pharmacology & Therapeutics. 88(2). 204–213. 32 indexed citations

15.

Candolfi, Marianela, Weidong Xiong, Kader Yagiz, et al.. (2010). Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proceedings of the National Academy of Sciences. 107(46). 20021–20026. 76 indexed citations

16.

Candolfi, Marianela, Kader Yagiz, David Foulad, et al.. (2009). Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity. Clinical Cancer Research. 15(13). 4401–4414. 80 indexed citations

17.

Muhammad, A.K.M. Ghulam, Marianela Candolfi, Gwendalyn D. King, et al.. (2009). Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression. Clinical Cancer Research. 15(19). 6113–6127. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact